Candriam S.C.A. Boosts Stake in McKesson Corporation $MCK

Candriam S.C.A. grew its position in shares of McKesson Corporation (NYSE:MCK) by 26.3% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 190,186 shares of the company’s stock after buying an additional 39,586 shares during the quarter. McKesson accounts for approximately 0.8% of Candriam S.C.A.’s investment portfolio, making the stock its 21st biggest holding. Candriam S.C.A.’s holdings in McKesson were worth $146,926,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. RFG Advisory LLC increased its position in shares of McKesson by 1.1% during the third quarter. RFG Advisory LLC now owns 1,794 shares of the company’s stock valued at $1,386,000 after acquiring an additional 19 shares during the last quarter. MCF Advisors LLC grew its stake in McKesson by 36.4% in the 3rd quarter. MCF Advisors LLC now owns 997 shares of the company’s stock valued at $771,000 after purchasing an additional 266 shares during the period. Kinsale Capital Group Inc. increased its position in shares of McKesson by 7.5% during the 3rd quarter. Kinsale Capital Group Inc. now owns 15,993 shares of the company’s stock valued at $12,355,000 after purchasing an additional 1,119 shares during the last quarter. Signature Estate & Investment Advisors LLC raised its stake in shares of McKesson by 1.7% during the 3rd quarter. Signature Estate & Investment Advisors LLC now owns 59,487 shares of the company’s stock worth $45,957,000 after purchasing an additional 1,016 shares during the period. Finally, Smartleaf Asset Management LLC raised its stake in shares of McKesson by 48.0% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,831 shares of the company’s stock worth $1,395,000 after purchasing an additional 594 shares during the period. 85.07% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on MCK shares. Wall Street Zen lowered shares of McKesson from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Evercore reissued an “outperform” rating and set a $1,000.00 target price on shares of McKesson in a research report on Thursday, November 6th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of McKesson in a report on Wednesday, December 10th. Robert W. Baird set a $968.00 price objective on McKesson in a research note on Wednesday, January 14th. Finally, Mizuho raised their target price on McKesson from $880.00 to $885.00 and gave the stock a “neutral” rating in a research report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, McKesson presently has an average rating of “Moderate Buy” and a consensus price target of $918.93.

Insider Transactions at McKesson

In other McKesson news, EVP Thomas L. Rodgers sold 276 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $816.18, for a total transaction of $225,265.68. Following the sale, the executive vice president owned 2,268 shares in the company, valued at $1,851,096.24. This trade represents a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.08% of the company’s stock.

Key Headlines Impacting McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Q3 results beat consensus: EPS topped estimates and revenue grew ~11.4% year‑over‑year; management raised FY‑2026 adjusted EPS guidance to $38.80–$39.20, underpinning today’s rally. McKesson Q3 Earnings Call Highlights
• Positive Sentiment: Growth drivers called out on the call: oncology, specialty distribution and technology businesses accelerated, which McKesson cites as the basis for the raised profit outlook. MCK Q3 Earnings & Sales Top Estimates, 2026 View Up
• Positive Sentiment: Strong market reaction: analysts and investors pushed the share price sharply higher on the beat + guidance, citing the bigger‑than‑expected lift to FY26 adjusted EPS. How McKesson Stock Surged 17% In A Day
• Neutral Sentiment: Analyst target changes mixed: some firms raised price targets (e.g., Wells Fargo, Mizuho) but ratings stayed neutral/equal‑weight, leaving upside expectations varied among brokers. Price Target Raised to $925.00 at Wells Fargo & Company
• Neutral Sentiment: Company materials and transcripts are available for detailed review (presentation and full earnings call transcript) — useful for checking segment KPIs, margin drivers and guidance assumptions. Q3 2026 earnings call transcript
• Negative Sentiment: Operational cash flow weakness flagged: some reports note weaker operating cash flow despite profit growth, and balance‑sheet metrics (higher liabilities) warrant watching for sustainability of buybacks/dividends. EPS Beats, Profit Growth but Weak Operating Cash Flow
• Negative Sentiment: Insider selling is noted in recent filings; combined with high share price momentum, this can contribute to near‑term volatility or profit‑taking. Insider Trading and Hedge Fund Activity

McKesson Stock Down 1.0%

MCK stock opened at $947.96 on Monday. The stock has a 50-day simple moving average of $828.41 and a two-hundred day simple moving average of $780.53. McKesson Corporation has a twelve month low of $583.55 and a twelve month high of $971.93. The firm has a market capitalization of $116.11 billion, a PE ratio of 27.26, a PEG ratio of 1.52 and a beta of 0.40.

McKesson (NYSE:MCK) last released its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, beating analysts’ consensus estimates of $9.19 by $0.15. The company had revenue of $106.16 billion during the quarter, compared to analyst estimates of $105.98 billion. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. McKesson’s revenue was up 11.4% compared to the same quarter last year. During the same period last year, the business earned $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, equities research analysts anticipate that McKesson Corporation will post 32.77 EPS for the current fiscal year.

McKesson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 1st. Stockholders of record on Monday, March 2nd will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, March 2nd. McKesson’s payout ratio is currently 9.43%.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.